vTv Therapeutics is a clinical-stage company developing cadisegliatin, an oral pill taken with insulin to reduce dangerous low blood sugar in type 1 diabetes; it is not approved.
vTv's case rests on cadisegliatin, an investigational oral liver-selective glucokinase activator added to insulin in type 1 diabetes. Phase 2 results support its potential; fully enrolled Phase 3 CATT1 evaluates level 2 and 3 hypoglycemia, with results expected mid 2027. The newly started Hybrid CATT1 pilot addresses closed-loop users excluded from CATT1. Cash was $86.6 million at June 30, 2026; management's earlier readout-linked runway guidance needs updating for the later timeline.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: CATT1 reduces serious low-blood-sugar events
Does cadisegliatin reduce level 2 and 3 hypoglycemic events with acceptable safety in CATT1?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Cadisegliatin's Phase 3 is fully enrolled; hypoglycemia results now expected mid 2027
Cadisegliatin's CATT1 Phase 3 readout will determine whether a BTD-designated insulin adjunct can redefine T1D management
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Blood disorders, Obesity, diabetes and heart disease
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
9 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.